SCHEMBL1849347

SCHEMBL1849347

CN(C)C(=O)C(=Cc1cccc([N+](=O)[O-])c1)c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
NPSR1 Q6W5P4 3/20 0.54
KMT2A Q03164 1/20 0.54
GLO1 Q04760 2/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
LMNA P02545 5/20 0.47
ALDH1A1 P00352 2/20 0.47
FBP1 P09467 1/20 0.47
TGM2 P21980 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
HIF1A Q16665 1/20 0.45
HTT P42858 3/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
PKM P14618 2/20 0.44
HPGD P15428 2/20 0.44
XBP1 P17861 2/20 0.44
S1PR2 O95136 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976364 1.00 MAPT (0.54) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL9434339 0.86 GLO1 (0.63) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL9434342 0.86 GLO1 (0.63) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL10846497 0.76 GLO1 (0.79) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL1849349 0.75 CES2 (0.55) MAPTNPSR1KMT2ASMN1; SMN2LMNA
SCHEMBL7828360 0.74 MAPT (0.62) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL11216772 0.74 MAPT (0.62) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL7828363 0.74 MAPT (0.62) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL9434390 0.73 GLO1 (0.61) MAPTNPSR1KMT2AGLO1SMN1; SMN2
SCHEMBL9434385 0.73 GLO1 (0.61) MAPTNPSR1KMT2AGLO1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 MAPT 3183/4885NPSR1 4391/4885KMT2A 1195/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 MAPT 3183/4885NPSR1 4391/4885KMT2A 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.